Gerresheimer AGXSWX:GXI 73 Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus rates XSWX:GXI with a GF Score™ of 73/100 and a GF Value™ of CHF87.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 348 Medical Devices & Instruments companies, Gerresheimer AG ranks worse than 287356.03% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Gerresheimer AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GXI vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gerresheimer AG (XSWX:GXI) has a Buyback Yield % of 0.00 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gerresheimer AG and its competitors. According to the industry distribution chart, Gerresheimer AG ranks #999999 out of 348 companies in the Medical Devices & Instruments industry.
Is Gerresheimer AG's Buyback Yield % too high?
Gerresheimer AG's current Buyback Yield % is 0.00. Based on the distribution chart, Gerresheimer AG ranks #999999 out of 348 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gerresheimer AG has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #999999 out of 348 companies for Buyback Yield %. This places Gerresheimer AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gerresheimer AG and its competitors. Gerresheimer AG's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (XSWX:GXI) is currently considered Possible Value Trap. The stock's GF Value™ is CHF87.96, compared to a current price of CHF25.02 — trading 71.6% below its estimated fair value. The current Buyback Yield % is 0.00. Gerresheimer AG's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Gerresheimer AG (XSWX:GXI), the current Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (XSWX:GXI) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of CHF25.02 is trading 71.6% below its estimated GF Value™ of CHF87.96.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for XSWX:GXI:
Buyback Yield %: 0.00
GF Value™: CHF87.96 vs. price of CHF25.02 (71.6% below fair value)
No single metric tells the full story. See the XSWX:GXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
73GF Score
Get the complete analysis for XSWX:GXI
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GXI has been successfully added to your 
